Abstracts

METFORMIN TREATMENT IN NONDIABETIC HIV-INFECTED INDIVIDUALS ON ART

The mechanistic target of rapamycin (mTOR) promotes HIV transcription. In line, we demonstrated that HIV preferentially targets gut-homing CCR6+Th17 cells for replication/persistence via mTOR-dependent mechanisms. Thus, mTOR inhibitors may limit residual HIV transcription during ART and subsequently reduce immune activation/inflammation. Here, we report results from a clinical trial conceived to evaluate the effect of 12…

METFORMIN THERAPY WITH IMMUNE CHECKPOINT INHIBITORS IMPACTS ANTI-HIV T-CELL RESPONSES

Despite suppressive antiretroviral therapy (ART), chronic HIV is associated with T cell exhaustion, defined by the overexpression of negative immune checkpoint receptors. The efficacy of immune checkpoint blockade (ICB) in reversing T cell dysfunction and improving cancer survival is variable. Metformin (MET) is an oral hypoglycemic therapy for type II diabetes and has previously unrecognized…

ZINC SUPPLEMENTATION AND INFLAMMATION IN TREATED HIV

In HIV, the prevalence of zinc deficiency appears to be high and low plasma zinc levels have been linked with disease progression and an increased risk of death. In this study, we explored the effect of zinc supplementation on the heightened state of inflammation and monocyte activation observed in ART-treated HIV infection. This is a…

GLYCOMIC DETERMINANTS OF INTERFERON-a MEDIATED REDUCTION OF HIV PERSISTENCE IN VIVO

Interferon-α (IFNα) therapy was associated with significant suppression of HIV viremia and reduction in levels of HIV DNA during suppressive antiretroviral therapy (ART). Cytokines modulate host glycosylation, and glycosylation plays a critical role in mediating several antibody (mainly immunoglobulin G; IgG) immunological functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and anti-inflammatory activities. Nevertheless, the impact of…

PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN

Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) strongly predicts viral suppression (VS) in people on antiretroviral (ARV) treatment but the assay is expensive and time-consuming. There are no data on the relative performance of DBS TFV-DP and plasma ARV concentrations to predict VS. A cross-sectional analysis was done among HIV-positive, non-pregnant, black South African women…

EXPANDING TESTING STRATEGIES IN PARIS: A FREE POSTAL COMPREHENSIVE STI TEST KIT

Testing is critical to HIV and other sexually transmitted infections (STI) treatment and prevention. The MemoDepistages multicenter study is a novel French government-based comprehensive STI testing program, providing free postal self-sampling kits to high-risk MSM. We present here the baseline results from the Paris area, accounting for 60% of all participants.   The program was…

DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ

We previously described 57% lower levonorgestrel (LNG) exposure in women receiving the LNG subdermal implant (standard dose, 150mg) with efavirenz (EFV)-based antiretroviral therapy (ART) compared to ART-naïve women. Three of 20 women (15%) had an unintended pregnancy within 48 weeks of LNG-EFV combined use, with observed LNG concentrations ≤303 pg/mL at the visit prior to…

POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE

Achieving the 90-90-90 targets will require efficient methods to monitor people living with HIV (PLHIV) on antiretroviral therapy (ART) in resource-limited settings. We compared point-of-care (POC) viral load (VL) testing to standard laboratory VL testing for achieving VL suppression and retention in care for PLHIV in Durban, South Africa.   We conducted an open-label, randomized…